دورية أكاديمية
Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma
| العنوان: | Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma |
|---|---|
| المؤلفون: | Videla Richardson, Guillermo, Morris Hanon, Olivia, Torres, Nicolás, Esquivel, Myrian Inés, Vera, Mariana Belén, Ripari, Luisina Belén, Croci Russo, Diego Omar, Sevlever, Gustavo, Rabinovich, Gabriel Adrián |
| بيانات النشر: | MDPI |
| المجموعة: | CONICET Digital (Consejo Nacional de Investigaciones Científicas y Técnicas) |
| مصطلحات موضوعية: | ANGIOGENESIS, CENTRAL NERVOUS SYSTEM, GALECTINS, GLIOBLASTOMA, GLYCANS, GLYCO-CHECKPOINTS, IMMUNOMODULATION, IMMUNOTHERAPY, INVASION, https://purl.org/becyt/ford/1.6Test, https://purl.org/becyt/ford/1Test |
| الوصف: | Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. Galectins, a family of glycan-binding proteins, are highly expressed in the tumor microenvironment (TME) and delineate prognosis and clinical outcome in patients with GBM. These endogenous lectins play key roles in different hallmarks of cancer by modulating tumor cell proliferation, oncogenic signaling, migration, vascularization and immunity. Additionally, they have emerged as mediators of resistance to different anticancer treatments, including chemotherapy, radiotherapy, immunotherapy, and antiangiogenic therapy. Particularly in GBM, galectins control tumor cell transformation and proliferation, reprogram tumor cell migration and invasion, promote vascularization, modulate cell death pathways, and shape the tumor-immune landscape by targeting myeloid, natural killer (NK), and CD8+ T cell compartments. Here, we discuss the role of galectins, particularly galectin-1,-3,-8, and-9, as emerging glyco-checkpoints that control different mechanisms associated with GBM progression, and discuss possible therapeutic opportunities based on inhibition of galectin-driven circuits, either alone or in combination with other treatment modalities. ; Fil: Videla Richardson, Guillermo. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina ; Fil: Morris Hanon, Olivia. Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina ; Fil: Torres, Nicolás. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina ; Fil: Esquivel, Myrian Inés. Fundación para la Lucha ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1661-6596 1422-0067 |
| العلاقة: | info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/23/1/316Test; http://hdl.handle.net/11336/201042Test; Videla Richardson, Guillermo; Morris Hanon, Olivia; Torres, Nicolás; Esquivel, Myrian Inés; Vera, Mariana Belén; et al.; Galectins as emerging glyco-checkpoints and therapeutic targets in glioblastoma; MDPI; International Journal of Molecular Sciences; 23; 1; 1-2022; 1-21; CONICET Digital; CONICET |
| الإتاحة: | https://doi.org/10.3390/ijms23010316Test http://hdl.handle.net/11336/201042Test |
| حقوق: | info:eu-repo/semantics/openAccess ; https://creativecommons.org/licenses/by-nc-sa/2.5/arTest/ |
| رقم الانضمام: | edsbas.B9DE3D76 |
| قاعدة البيانات: | BASE |
| تدمد: | 16616596 14220067 |
|---|